PeptideKey News
Pfizer VESPER-3 Phase 2b: monthly GLP-1 injection PF-08653944 achieves 12.3% weight loss at 28 weeks with no plateau. 10 Phase 3 trials launching 2026.
This article is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.